MSI-1256F (Squalamine Lactate)

DRUG3 trials

Sponsors

Genaera Corporation

Conditions

Macular Degeneration

Phase 2

A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat Wet Age-Related Macular Degeneration

TerminatedNCT00089830

Genaera CorporationMacular Degeneration

Start: 2004-08-31End: 2007-05-31Target: 120Updated: 2007-11-28

MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With Wet Age-Related Macular Degeneration (AMD)

TerminatedNCT00094120

Genaera CorporationMacular Degeneration

Start: 2004-10-31End: 2007-02-28Target: 60Updated: 2008-01-09

A Study of MSI-1256F (Squalamine Lactate) To Treat Wet Age-Related Macular Degeneration

TerminatedNCT00333476

Genaera CorporationMacular Degeneration

Start: 2006-05-31Target: 140Updated: 2007-11-28